GenScript Biotech Announces 2023 Annual Results with a Five-Year CAGR stands at 30%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
JPMorgan on Legend Biotech Corp. (LEGN): 'Remain Confident in Carvykti’s Profile Post ODAC Briefing Docs'
March 13, 2024 12:10 PM EDTJPMorgan analyst Jessica Fye reiterated an Overweight rating on Legend Biotech Corp. (NASDAQ: LEGN).
The analyst comments "While we expect the FDAs question around the imbalance in early death in CARTITUDE-4 to be taken seriously at Fridays ad com on Carvykti, the data around early deaths show it... More
